Navigation

Retavase (Centocor)

Retavase (Centocor) - General Information

Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).

 

Pharmacology of Retavase (Centocor)

Retavase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

 

Retavase (Centocor) for patients

 

Retavase (Centocor) Interactions

The interaction of Retavase� with other cardioactive drugs has not been studied. In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase� therapy.

 

Retavase (Centocor) Contraindications

Because thrombolytic therapy increases the risk of bleeding, Retavase� is contraindicated in the following situations:

 

Additional information about Retavase (Centocor)

Retavase (Centocor) Indication: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Mechanism Of Action: Retavase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Reteplase
Synonyms: Tissue-type plasminogen activator precursor; t- PA; t-plasminogen activator; tPA
Drug Category: Thrombolytic Agents
Drug Type: Biotech; Approved

Other Brand Names containing Reteplase: Retavase (Centocor); Retavase (Roche);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Retavase (Centocor): Injection, powder, lyophilized, for solution Intravenous bolus
Chemical IUPAC Name: Human tissue plasminogen activator fragment
Chemical Formula: C1736H2671N499O522S22
Reteplase on Wikipedia: https://en.wikipedia.org/wiki/Reteplase
Organisms Affected: Humans and other mammals